Legend Biotech (LEGN) Receivables (2019 - 2025)

Legend Biotech has reported Receivables for 7 years, with the latest figure at $13.1 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 82.45% year-over-year to $13.1 million; the trailing twelve-month figure through Dec 2025 stood at $13.1 million (up 82.45% YoY), and the FY2025 full-year result was $13.1 million, up 85.37% from the prior year.
• Receivables for Q4 2025 stood at $13.1 million, up from $1.2 million in the prior quarter.
• The five-year high for Receivables was $100.8 million in Q4 2023, with the low at $1967.0 in Q1 2021.
• Historically, Receivables has averaged $16.8 million across 5 years, with a median of $5.2 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables jumped 2564770.36% — and 2023, when it sank 99.89%.
• Legend Biotech's Receivables stood at $51.2 million in 2021, then slumped by 97.97% to $1.0 million in 2022, then jumped by 9613.97% to $100.8 million in 2023, then slumped by 92.88% to $7.2 million in 2024, then jumped by 82.45% to $13.1 million in 2025.
• The last three Receivables figures came in at $13.1 million (Q4 2025), $1.2 million (Q3 2025), and $27.6 million (Q2 2025), per Business Quant data.